|
1
|
Varelas C, Gavriilaki E. Sickle Cell Disease: Current Understanding and Future Options. J Clin Med 2023; 12:5943. [PMID: 37762884 PMCID: PMC10532277 DOI: 10.3390/jcm12185943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Accepted: 08/17/2023] [Indexed: 09/29/2023] Open
Abstract
Sickle cell disease (SCD) is a prevalent inherited hemoglobin disorder encompassing a cluster of congenital hemolytic anemias, each distinguished by the prevalence of sickle hemoglobin (HbS) [...].
Collapse
Affiliation(s)
- Christos Varelas
- Hematology Department—BMT Unit, G .Papanicolaou Hospital, 57010 Thessaloniki, Greece
| | - Eleni Gavriilaki
- 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54644 Thessaloniki, Greece
| |
Collapse
|
|
2
|
Nakahara H, Cheedarla N, Verkerke HP, Cheedarla S, Wu SC, Hendrickson JE, Chang A, McLemore ML, El Rassi F, Roback JD, Neish AS, Fasano RM, Stowell SR. Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease. Br J Haematol 2023; 202:937-941. [PMID: 37287128 PMCID: PMC10751105 DOI: 10.1111/bjh.18899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/19/2023] [Accepted: 05/22/2023] [Indexed: 06/09/2023]
Abstract
Patients with sickle cell disease (SCD) are considered to be immunocompromised, yet data on the antibody response to SARS-CoV-2 vaccination in SCD is limited. We investigated anti-SARS-CoV-2 IgG titres and overall neutralizing activity in 201 adults with SCD and demographically matched non-SCD controls. Unexpectedly, patients with SCD generate a more robust and durable COVID-19 vaccine IgG response compared to matched controls, though the neutralizing activity remained similar across both cohorts. These findings suggest that patients with SCD achieve a similar antibody response following COVID-19 vaccination compared to the general population, with implications for optimal vaccination strategies for patients with SCD.
Collapse
Affiliation(s)
- Hirotomo Nakahara
- Center for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Narayanaiah Cheedarla
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Hans P Verkerke
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Suneethamma Cheedarla
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Shang-Chuen Wu
- Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Jeanne E Hendrickson
- Center for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA
| | - Andres Chang
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Morgan L McLemore
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Fuad El Rassi
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
| | - John D Roback
- Center for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Andrew S Neish
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ross M Fasano
- Center for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sean R Stowell
- Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
|
3
|
Joseph L, Corbasson A, Manceau S, Khimoud D, Meunier B, Cheminet G, Lefrere F, Jannot AS, Lu E, Arlet JB. Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease. Br J Haematol 2023; 200:563-567. [PMID: 36354234 PMCID: PMC9877809 DOI: 10.1111/bjh.18547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 09/30/2022] [Accepted: 10/19/2022] [Indexed: 11/11/2022]
Abstract
Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.
Collapse
Affiliation(s)
- Laure Joseph
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.,Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France
| | - Anne Corbasson
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Sandra Manceau
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.,Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France
| | - Djamal Khimoud
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Benoit Meunier
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Geoffrey Cheminet
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.,Faculty of Medicine, Université de Paris Cité, Paris, France
| | - François Lefrere
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Anne-Sophie Jannot
- Faculty of Medicine, Université de Paris Cité, Paris, France.,Department of Medical Informatics, Biostatistics, and Public Health, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Estelle Lu
- Department of Medical Informatics, Biostatistics, and Public Health, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Jean-Benoît Arlet
- Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France.,Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.,Faculty of Medicine, Université de Paris Cité, Paris, France.,INSERM U1163, CNRS 8254, Institut IMAGINE, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| |
Collapse
|
|
4
|
Han J, Zhang X, Molokie RE, Njoku FU, Hussain FA, Farooqui M, Rizvi I, Saraf SL, Gordeuk VR. COVID-19 vaccination status and disease burden in patients with sickle cell disease. Br J Haematol 2022; 199:e21-e24. [PMID: 36058234 PMCID: PMC9538477 DOI: 10.1111/bjh.18443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 08/14/2022] [Accepted: 08/19/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Jin Han
- Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.,Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Xu Zhang
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Robert E Molokie
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.,Department of Medicine, Jesse Brown VA Medical Center, Chicago, Illinois, USA
| | - Franklin U Njoku
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Faiz A Hussain
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Marwah Farooqui
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Insia Rizvi
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Santosh L Saraf
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| | - Victor R Gordeuk
- Division of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
| |
Collapse
|
|
5
|
Green NS, Van Doren L, Licursi M, Billings DD, Sandoval LA, Feit YMZ, Hod EA. Anti-SARS-CoV-19 antibodies in children and adults with sickle cell disease: A single-site analysis in New York City. Br J Haematol 2022; 198:680-683. [PMID: 35759223 PMCID: PMC9350182 DOI: 10.1111/bjh.18294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 05/18/2022] [Accepted: 05/19/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Nancy S Green
- Department of Pediatrics, Division of Hematology, Oncology and Stem Cell Transplantation, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA.,Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA
| | - Layla Van Doren
- Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA
| | - Maureen Licursi
- Department of Pediatrics, Division of Hematology, Oncology and Stem Cell Transplantation, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA
| | - Daniel D Billings
- Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA
| | - Luke A Sandoval
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA
| | - Yona M Z Feit
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA
| | - Eldad A Hod
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center - New York Presbyterian Hospital, New York, New York, USA
| |
Collapse
|